James N.  Woody net worth and biography

James Woody Biography and Net Worth

James N. Woody, M.D., Ph.D has more than 25 years of pharmaceutical research and management expertise.

He has served as our Chief Executive Officer and as a director since the closing of the business combination in November 2020. Dr. Woody has served as the CEO of 180 since July 2020, and as a director of 180 Life Sciences since September 2020.

Dr. Woody was a founder and served as Chairman of the Board of Directors for Viracta Pharmaceuticals, a lymphoma therapeutic company (2014 to 2020). With the company undergoing a reverse merger into a public company, he resigned his Board member position and continues as a Board observer.

He has served in a variety of health and management roles including as President of Roche Bioscience, and CSO and Senior Vice President of R&D for Centocor.

At Centocor, Jim was part of the team that discovered Remicade, used to treat arthritis and which is now one of the best-selling drugs in the world.

He served as Commanding Officer and Director at the US Naval Medical Research and Development Command in Bethesda, Maryland.

In this role he was responsible for the surveillance, detection and therapy for all biologic warfare agents and infectious diseases in the First Gulf War; he was awarded the US Navy Legion of Merit for his service.

He holds an MD from Loma Linda University, and trained in pediatric immunology at Duke University and Boston Children’s Hospital (Harvard).

He further holds a PhD in Immunology from the University of London and has co-authored more than 140 publications.

What is James N. Woody's net worth?

The estimated net worth of James N. Woody is at least $4,099.44 as of May 18th, 2023. Dr. Woody owns 2,204 shares of 180 Life Sciences stock worth more than $4,099 as of December 21st. This net worth estimate does not reflect any other assets that Dr. Woody may own. Additionally, Dr. Woody receives a salary of $617,770.00 as CEO at 180 Life Sciences. Learn More about James N. Woody's net worth.

How old is James N. Woody?

Dr. Woody is currently 82 years old. There are 3 older executives and no younger executives at 180 Life Sciences. Learn More on James N. Woody's age.

What is James N. Woody's salary?

As the CEO of 180 Life Sciences Corp., Dr. Woody earns $617,770.00 per year. Learn More on James N. Woody's salary.

How do I contact James N. Woody?

The corporate mailing address for Dr. Woody and other 180 Life Sciences executives is 30 PARK PLACE SUITE 45E, NEW YORK NY, 10007. 180 Life Sciences can also be reached via phone at (650) 507-0669 and via email at [email protected]. Learn More on James N. Woody's contact information.

Has James N. Woody been buying or selling shares of 180 Life Sciences?

James N. Woody has not been actively trading shares of 180 Life Sciences during the past quarter. Most recently, on Thursday, May 18th, James N. Woody bought 2,105 shares of 180 Life Sciences stock. The stock was acquired at an average cost of $19.57 per share, with a total value of $41,194.85. Following the completion of the transaction, the chief executive officer now directly owns 2,204 shares of the company's stock, valued at $43,132.28. Learn More on James N. Woody's trading history.

Who are 180 Life Sciences' active insiders?

180 Life Sciences' insider roster includes Donald McGovern, Jr. (Director), Ozan Pamir (CFO), Quan Vu (COO), and James Woody (CEO). Learn More on 180 Life Sciences' active insiders.

James N. Woody Insider Trading History at 180 Life Sciences

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/18/2023Buy2,105$19.57$41,194.852,204View SEC Filing Icon  
12/9/2021Buy32$1,622.60$51,923.20View SEC Filing Icon  
See Full Table

James N. Woody Buying and Selling Activity at 180 Life Sciences

This chart shows James N Woody's buying and selling at 180 Life Sciences by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

180 Life Sciences Company Overview

180 Life Sciences logo
180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed Phase IIb clinical trials that focuses on fibrosis and anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. 180 Life Sciences Corp. is headquartered in Palo Alto, California.
Read More

Today's Range

Now: $1.86
Low: $1.86
High: $2.02

50 Day Range

MA: $2.88
Low: $1.36
High: $6.47

2 Week Range

Now: $1.86
Low: $1.16
High: $17.75

Volume

52,501 shs

Average Volume

732,560 shs

Market Capitalization

$1.91 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.12